DEAL OR NO DEAL? GENERIC DRUG EDITION.

Here's one that slipped by me: the April 25 news that because of a pharma-favorable appeals court ruling, brand name pharmaceutical companies are once again paying off generic drug companies to delay marketing their cheaper products.

Here's a classic case of the mixed motives of our government branches, and how corporations get and use legal workarounds -- the Federal Trade Commission goes after pharmas after courts throw out FTC enforcement of a law passed by Congress to end pharmas' generic-blocking deals, which are workarounds to Food and Drug Administration regulations.

>> Washington Post story
>> Thanks to SeniorJournal.com, where I found the original story.